Q5107 – Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
HCPCS Level II code · Q codes: Temporary Codes
HCPCS codeQ5107
- Long description
- Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Short description
- Inj mvasi 10 mg
- Pricing indicator
51Drugs- Medicare coverage
DSpecial coverage instructions apply- BETOS category
O1EOther drugs- Added
- January 1, 2019
- Last change
- January 1, 2019 – No change
Frequently asked questions
What is HCPCS code Q5107?
Q5107 is a HCPCS Level II code for injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg.
Does Medicare cover Q5107?
The HCPCS file lists coverage code D: Special coverage instructions apply. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby Q codes
- Q5099 – Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg
- Q5100 – Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
- Q5101 – Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5102 – Injection, infliximab, biosimilar, 10 mg
- Q5103 – Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104 – Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105 – Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106 – Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5108 – Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5109 – Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
- Q5110 – Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111 – Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
- Q5112 – Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg
- Q5113 – Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg
- Q5114 – Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg
- Q5115 – Injection, rituximab-abbs, biosimilar, (truxima), 10 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.